Life Sciences Consortium (LSC)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2005
  • Initiating Organization: CEO Roundtable on Cancer
  • Initiator Type: Third-party organization
  • Disease focus:
    Oncology
  • Location: North America

Abstract

The Life Sciences Consortium (LSC) is a task force of the CEO Roundtable on Cancer. LSC was formed in 2005 to bring together selected CEO Roundtable on Cancer member companies to build collaboration that enables a transformation in research and development (R&D) activities that will deliver more effective therapies to patients faster. LSC hopes that its website visitors will use its resources and share their own relevant insights in a collaborative effort to better serve cancer patients worldwide.

Mission

LSC’s overarching goal is to enable member companies to work together to remove roadblocks and to find new ways to accelerate discovery and development of new therapies for all cancer patients.

Specific tactics include the following:

Consortium History

An LSC Task Force was commissioned during the fourth annual meeting of the CEO Roundtable on Cancer in June 2003. The Task Force was asked to explore the creation of a forum to enhance and speed cancer drug discovery and early drug development, thereby bringing improved therapies to cancer patients faster. LSC was charged with exploring the formation of a consortium that would unite the research-intensive pharmaceutical and biotech industry with each other, as well as with the National Cancer Institute, Centers for Disease Control and Prevention, U.S. Food and Drug Administration, and academic centers of excellence.

Impact/Accomplishment

Project Data Sphere, LLC, an independent, not-for-profit initiative of LSC, operates the Project Data Sphere® platform  (www.ProjectDataSphere.org), which provides one place where the research community can broadly share, integrate, and analyze historical, patient-level, cancer Phase III comparator-arm data with the goal of advancing future research to improve the lives of cancer patients and their families around the world.

The START clauses represent a toolkit that provides standardized legal language for key agreement elements common to most clinical trial agreements. By starting the negotiation process with commonly agreed upon language, the START clauses can simplify and accelerate the contracting process. Although developed with cancer clinical trials in mind, the START clauses are applicable to all types of clinical research.

Points of Contact

Gregory A. Curt
Co-Chair, Life Sciences Consortium
email: Gregory.Curt@astrazeneca.com

Mace Rothenberg
Co-Chair, Life Sciences Consortium
email: Mace.Rothenberg@pfizer.com

Sponsors & Partners

Amgen

Astellas Pharma, Inc.

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals

Celgene

Centocor R&D USA

CEO Roundtable on Cancer

Covance

Duke University School of Medicine

Eli Lilly and Company

H. Lee Moffitt Cancer Center and Research Institute

Hogan Lovells US LLP

Institute of Medicine

Johnson & Johnson

MD Anderson Cancer Center

MedImmune

Mehta Partners

Novartis

Pfizer, Inc.

PPD

Quintiles Transnational

Sanofi

SAS

The LIVESTRONG Foundation

The National Cancer Institute


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.